09 Jan 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Business intelligence provider GlobalData estimates that India is expected to exhibit a great surge in H1N1 vaccine demand over the next 10 years, climbing at an annual growth rate of 2.1 percent.
However, despite this relative growth, the percentage of influenza-vaccinated citizens in the country will only be 1.7 percent of the population by 2022. According to GlobalData's latest epidemiology report, seasonal influenza vaccine demand in the US will also increase from the estimated 142 million in 2012 to 158 million in 2022, a growth rate of 1.2 percent.
The new GlobalData report says that the primary driver for the predicted growth in influenza vaccine demand will be a general increase in the US population and the corresponding rise in those classified as high-risk, such as the elderly or those with pre-existing conditions.